Periarticular Hydroxyapatite Masses | FGF23/GALNT3 Pathway | Hip, Shoulder, Elbow
PATHOLOGIC CLASSIFICATION
Critical Must-Knows
- Periarticular lobulated masses of calcium hydroxyapatite, not a true neoplasm
- Hip, shoulder, elbow and wrist are the classic sites; mass often grows over years
- Hyperphosphataemic type = GALNT3, FGF23 or KLOTHO loss-of-function - phosphate retention
- Secondary type is far more common than familial, and is driven by chronic renal failure
- X-ray: lobulated, 'cloud-like' or 'chicken-wire' periarticular calcification is characteristic
- Biopsy is usually diagnostic; differentiate from parosteal osteosarcoma, myositis ossificans, tophaceous gout
Clinical Pearls
- "Serum calcium is normal, phosphate is high (in familial hyperphosphataemic type) - 1,25-(OH)2 vitamin D is suppressed
- "Chalky white 'toothpaste' discharge through skin is pathognomonic in ulcerated cases
- "Myositis ossificans forms mature lamellar bone attached to periosteum - tumoral calcinosis does not
- "Recurrence after excision is the rule, not the exception, in familial disease
- "Acetazolamide and phosphate binders (sevelamer, lanthanum) are first-line metabolic therapy
Critical Tumoral Calcinosis Exam Points
Pathogenesis
Periarticular calcium hydroxyapatite deposition. In familial (primary hyperphosphataemic) disease, loss-of-function mutations in GALNT3, FGF23 or KLOTHO impair FGF23 signalling, causing renal phosphate retention and hyperphosphataemia. The deposited mineral is calcium phosphate (hydroxyapatite), not calcium oxalate or calcium pyrophosphate.
Common Sites
Hip greater than shoulder greater than elbow greater than wrist. The masses sit adjacent to but not within the joint, often along the trochanteric bursa, subdeltoid bursa, or olecranon. Lesions are lobulated, can exceed 20 cm, and may ulcerate through skin discharging chalky material.
Classification by Phosphate
Hyperphosphataemic familial (FGF23 axis) vs normophosphataemic primary vs secondary uraemic vs dystrophic. Always check serum calcium, phosphate, PTH, 25-OH vitamin D, 1,25-(OH)2 vitamin D, creatinine, and urinary phosphate. Familial disease typically presents in the 1st-2nd decade.
Treatment
Metabolic first, surgery for symptoms. Phosphate binders (sevelamer, lanthanum), low-phosphate diet, and acetazolamide reduce phosphate load. Surgical excision is reserved for symptomatic, ulcerating, mechanically limiting or diagnostically uncertain masses. Recurrence is the rule in familial disease, often approaching 100 percent after simple debulking.
Quick Decision Guide - Tumoral Calcinosis
| Type | Phosphate | Clinical Clue | First-Line Treatment | Surgical Prognosis |
|---|---|---|---|---|
| Primary hyperphosphataemic (familial) | Elevated (often greater than 2 mmol/L) | Child/young adult, sibling cases, no renal disease | Phosphate binder + acetazolamide + low-P diet | High recurrence (often greater than 50%) |
| Primary normophosphataemic (sporadic) | Normal | Solitary mass, no metabolic abnormality | Excision if symptomatic | Low recurrence if completely excised |
| Secondary (CKD / dialysis) | Often elevated, with high PTH and Ca-P product | Adult on long-term dialysis, multiple joints | Manage CKD-MBD, parathyroidectomy if needed | Recurrence common unless metabolic state corrected |
| Dystrophic / other (trauma, hyperparathyroidism, vitamin D) | Variable | Local tissue damage or systemic metabolic driver | Treat underlying cause, excision of mass | Depends on cause control |
TUMORALClinical Presentation of Tumoral Calcinosis
| T | Tumefaction Firm, painless, deep periarticular mass |
| U | Unilateral Usually single limb or single joint |
| M | Multilobulated Chicken-wire or cloud-like internal architecture |
| O | Over large joints Hip, shoulder, elbow, wrist |
| R | Radiodense Chalky-white calcification on plain X-ray |
| A | Adolescent onset Familial forms present 1st-2nd decade |
| L | Long, slow growth Years of progressive enlargement |
| T | Tumefaction Firm, painless, deep periarticular mass | O | Over large joints Hip, shoulder, elbow, wrist | L | Long, slow growth Years of progressive enlargement |
| U | Unilateral Usually single limb or single joint | R | Radiodense Chalky-white calcification on plain X-ray | ||
| M | Multilobulated Chicken-wire or cloud-like internal architecture | A | Adolescent onset Familial forms present 1st-2nd decade |
Hook:TUMORAL masses are not tumours - they are periarticular calcium hydroxyapatite deposits.
PHOSPHATEHyperphosphataemic Familial Type
| P | Plasma phosphate up Hyperphosphataemia, normal calcium |
| H | Hyperphosphataemia Often greater than 2 mmol/L in adults |
| O | O-linked glycosylation defect GALNT3 mutation prevents FGF23 activation |
| S | Suppressed 1,25-(OH)2D Loss of FGF23-driven 1-alpha hydroxylase |
| P | Phosphate binders Sevelamer or lanthanum first-line |
| H | Hydroxyapatite Calcium phosphate crystal deposition |
| A | Acetazolamide Carbonic anhydrase inhibitor increases P excretion |
| T | Treat metabolic first Surgery rarely cures familial disease |
| E | Excision if symptomatic Ulceration, nerve compression, cosmesis |
| P | Plasma phosphate up Hyperphosphataemia, normal calcium | S | Suppressed 1,25-(OH)2D Loss of FGF23-driven 1-alpha hydroxylase | A | Acetazolamide Carbonic anhydrase inhibitor increases P excretion |
| H | Hyperphosphataemia Often greater than 2 mmol/L in adults | P | Phosphate binders Sevelamer or lanthanum first-line | T | Treat metabolic first Surgery rarely cures familial disease |
| O | O-linked glycosylation defect GALNT3 mutation prevents FGF23 activation | H | Hydroxyapatite Calcium phosphate crystal deposition | E | Excision if symptomatic Ulceration, nerve compression, cosmesis |
Hook:PHOSPHATE captures the entire metabolic story of familial tumoral calcinosis.
RECURRINGSurgical and Prognostic Pearls
| R | Renal failure Most common cause is CKD on dialysis |
| E | Excise only if symptomatic Mechanical, ulcerating or diagnostic doubt |
| C | Ca-phosphate product Often elevated; drives secondary disease |
| U | Unresectable at times Encases neurovascular structures |
| R | Recurrence rate high Over 50% in familial, often near 100% |
| R | Renal transplant helps Resolves secondary type if graft functions |
| I | Investigate metabolic cause Never excise without workup |
| N | NSAIDs no role Metabolic, not inflammatory, process |
| G | Genetic testing GALNT3, FGF23, KLOTHO in familial cases |
| R | Renal failure Most common cause is CKD on dialysis | U | Unresectable at times Encases neurovascular structures | I | Investigate metabolic cause Never excise without workup |
| E | Excise only if symptomatic Mechanical, ulcerating or diagnostic doubt | R | Recurrence rate high Over 50% in familial, often near 100% | N | NSAIDs no role Metabolic, not inflammatory, process |
| C | Ca-phosphate product Often elevated; drives secondary disease | R | Renal transplant helps Resolves secondary type if graft functions | G | Genetic testing GALNT3, FGF23, KLOTHO in familial cases |
Hook:Tumoral calcinosis is RECURRING - prevention is the only cure for the familial form.
Overview and Epidemiology
Why This Matters
Tumoral calcinosis is a frequently missed cause of a periarticular 'tumour' in young patients. It is not a neoplasm - it is a metabolic deposition of calcium hydroxyapatite, almost always driven by either an inherited FGF23-axis defect (rare, familial, paediatric) or chronic renal failure with disordered mineral metabolism (common, adult, dialysis-dependent). A correct diagnosis changes management completely: surgery cures neither the familial form (it always recurs) nor the uraemic form (unless the metabolic state is corrected).
Epidemiology
- Rare disease: overall incidence estimated at roughly 1 in 100,000 to 1 in 1,000,000
- Familial (primary hyperphosphataemic): autosomal recessive, presents in 1st-2nd decade, often in children of consanguineous parents; described in clusters from the Middle East, North Africa and Turkey
- Secondary (uraemic): the clinically dominant form, rising in prevalence with the dialysis population
- Endemic reports: high-frequency clusters described in parts of sub-Saharan Africa and Papua New Guinea, often associated with low calcium, high phosphate dietary patterns
- Sex: familial form shows no strong sex predilection; secondary form tracks with CKD demographics
Why Surgeons See It
- Diagnostic confusion with bone or soft-tissue tumour - biopsy or excision is the typical referral pathway
- Mechanical symptoms - large masses restrict joint motion, irritate bursa, compress nerves
- Skin breakdown - ulceration with chalky 'toothpaste' discharge (pathognomonic when present)
- Functional limitation - sitting, walking, dressing all impaired
- Recurrence after incomplete excision - the single most common reason for repeated referrals
Pathophysiology
Tumoral Calcinosis is a Mineral Deposition Disorder, Not a Tumour
The mineral is calcium hydroxyapatite (calcium phosphate), deposited in lobulated sheets within periarticular soft tissue, often with a foreign-body giant cell reaction. There is no cellular atypia. The mass is not encapsulated and tends to insinuate around tendons, bursae and neurovascular structures, which is what makes complete excision surgically challenging and recurrence common.
Pathogenesis by Subtype
| Subtype | Driver | Lab Pattern | Histology | Recurrence Risk |
|---|---|---|---|---|
| Primary hyperphosphataemic (familial) | GALNT3, FGF23 or KLOTHO loss-of-function - renal phosphate retention | High PO4, normal Ca, suppressed 1,25-(OH)2D, normal/low PTH | Lobulated hydroxyapatite with giant cells | Very high (often greater than 50%) |
| Primary normophosphataemic (sporadic) | Unknown, possibly post-traumatic, local tissue injury | Normal serum calcium and phosphate | Lobulated hydroxyapatite, often solitary | Low if completely excised |
| Secondary (CKD / dialysis) | Hyperphosphataemia, secondary hyperparathyroidism, high Ca-P product, vitamin D analogues | High PO4, high PTH, variable Ca, low/normal vitamin D | Multilobulated periarticular calcium deposits | Common if metabolic state uncontrolled |
| Dystrophic / other | Local tissue damage (trauma, surgery) or systemic drivers (hyperparathyroidism, vitamin D toxicity, milk-alkali) | Depends on cause | Calcification within damaged tissue | Depends on cause control |
FGF23-GALNT3-KLOTHO Axis
FGF23 is secreted by osteocytes and osteoblasts in response to phosphate load and active vitamin D. Active FGF23 requires O-linked glycosylation by GALNT3 to be secreted in an intact form. KLOTHO is the co-receptor in the kidney.
In the familial hyperphosphataemic type: biallelic loss-of-function of any of these three genes (GALNT3 most common) prevents FGF23 signalling, abolishing renal phosphate wasting and 1-alpha-hydroxylase suppression.
Net result: phosphate retention, hyperphosphataemia, suppressed 1,25-(OH)2 vitamin D, normal calcium, normal or low PTH, and progressive periarticular hydroxyapatite deposition.
Secondary (Uraemic) Tumoral Calcinosis
CKD-Mineral and Bone Disorder (CKD-MBD) is the umbrella term. As GFR falls below roughly 30 mL/min/1.73 m^2, phosphate excretion fails, FGF23 rises, active vitamin D falls, and PTH rises (secondary hyperparathyroidism).
Drivers of soft-tissue calcification in CKD include: hyperphosphataemia, raised calcium-phosphate product, calciphylaxis-spectrum small-vessel disease, vitamin D analogue dosing, and use of calcium-based phosphate binders.
Tumoral calcinosis lesions in dialysis patients can reach enormous size at the hip, shoulder, elbow, hand or wrist, and frequently ulcerate.
Why the Lesion Forms Where It Does
The deposits form at sites of microtrauma, repeated shear or bursal friction - explaining the predilection for the greater trochanteric bursa, subdeltoid bursa, olecranon bursa and ischial region. The combination of local tissue injury, alkaline local pH, and high extracellular phosphate favours hydroxyapatite (rather than calcium oxalate) precipitation. The mineral is rarely within the joint itself.
Classification and Types
Pathogenesis-Based Classification (Smack 1996)
| Type | Phosphate | Typical Patient | Distribution |
|---|---|---|---|
| Primary hyperphosphataemic (familial) | Elevated, often greater than 2 mmol/L | Child or young adult, autosomal recessive, no renal disease | Hip, shoulder, elbow; can be multifocal |
| Primary normophosphataemic (sporadic) | Normal | Any age, often solitary, no systemic disease | Hip, elbow, hand |
| Secondary (uraemic, dialysis-related) | Elevated, with high PTH and Ca-P product | Adult on long-term dialysis or advanced CKD | Hip, shoulder, hand, wrist; often multiple sites |
| Dystrophic / other | Variable | Local trauma, hyperparathyroidism, vitamin D toxicity, milk-alkali, connective tissue disease | Often single, at site of injury or systemic driver |
Pathogenesis matters because it dictates whether the disease is curable, controllable or simply manageable.
Clinical Assessment
History
- Mass duration: years of slow, often painless growth is the rule
- Pain: usually late, when mass irritates bursa, compresses nerve or ulcerates skin
- Discharge: chalky white 'toothpaste' through skin is pathognomonic
- Renal disease: dialysis vintage, transplant status, medications (calcium-based binders, vitamin D analogues)
- Family history: sibling or parental cases (autosomal recessive)
- Diet and drugs: high phosphate intake, vitamin D supplementation, calcium supplements
Examination
- Mass: firm, lobulated, 'stony-hard', non-tender, often warm but not inflamed
- Mobility: usually fixed to deep soft tissues, not to skin (until late)
- Skin: tethering, erythema, ulceration, sinus tracts
- Joint: range often preserved unless mass mechanically blocks it
- Neurovascular: document function pre-op (sciatic at hip, axillary at shoulder, ulnar at elbow)
- Lymph nodes: not enlarged (reassuring against malignancy)
Clinical Tests for Tumoral Calcinosis
| Finding | Significance | Sensitivity | Specificity |
|---|---|---|---|
| Chalky 'toothpaste' discharge | Pathognomonic hydroxyapatite extrusion | Low (most masses are intact) | Very high |
| Stony-hard lobulated mass | Distinguishes from solid tumour, lipoma, ganglion | Moderate | Moderate |
| X-ray: lobulated periarticular calcification | Pattern recognition: 'cloud-like' or 'chicken-wire' | High | High in typical site |
| Serum phosphate elevation with normal calcium | Suggests primary hyperphosphataemic type | High in familial, low in secondary | High for familial type |
| Failure of mass to reduce with dialysis / binder therapy | Suggests mature, organised deposit needing excision | N/A | N/A |
Differentiating from Parosteal Osteosarcoma
Parosteal osteosarcoma arises from the periosteal surface, often of the posterior distal femur, with mature lamellar bone attached to the cortex and a 'string sign' (linear gap between tumour and cortex) on CT. Tumoral calcinosis is not attached to bone, is lobulated and amorphous (not bone-density), and does not invade cortex. When in doubt, biopsy before definitive surgery - and do not biopsy parosteal osteosarcoma through the planned resection tract.
Differential Diagnosis of a Periarticular Calcified Mass
| Condition | Typical Site | Key Feature | Discriminating Test |
|---|---|---|---|
| Tumoral calcinosis | Hip, shoulder, elbow, periarticular | Lobulated, periarticular, not attached to bone | X-ray pattern, serum phosphate, biopsy |
| Myositis ossificans | Muscle belly (quadriceps, brachialis) | Mature lamellar bone, attached to periosteum over weeks | X-ray shows ossified rim with lucent centre; serial imaging |
| Parosteal osteosarcoma | Posterior distal femur, proximal tibia, proximal humerus | Cortically based, mature bone, 'string sign' | CT, MRI, biopsy (only by sarcoma surgeon) |
| Synovial (osteo)chondromatosis | Intra-articular, knee, elbow, hip | Multiple intra-articular loose bodies, not periarticular mass | MRI, joint aspiration, arthroscopy |
| Tophaceous gout | First MTP, ear, olecranon, Achilles | Soft tissue tophi, may calcify, hyperuricaemia | Serum urate, joint aspiration (urate crystals) |
| Calcinosis circumscripta (CREST, scleroderma) | Fingertips, extensor surfaces | Small, multiple, skin-level calcifications | Clinical, ANA, capillaroscopy |
| Calcific tendinopathy of rotator cuff | Supraspinatus tendon | Hydroxylapatite within tendon, not lobulated mass | X-ray, ultrasound |
| Hyperparathyroidism with soft-tissue calcification | Periarticular, vascular | Raised PTH, raised calcium in primary | Serum PTH, calcium, ultrasound of neck |
Investigations
Diagnostic Workup
Views: AP and lateral of the involved joint, plus a long-bone view
Look for: Lobulated, dense periarticular calcification; 'cloud-like' or 'chicken-wire' internal architecture; corticated or un-corticated margin; no bony attachment; no periosteal reaction
Sensitivity: High in typical site; can be diagnostic in familial or uraemic disease
Indication: Surgical planning, exclude bony attachment, confirm lobulated architecture
Look for: No continuity with cortex, no marrow involvement, no soft-tissue mass with calcified matrix suggesting sarcoma
Use: Differentiate from parosteal osteosarcoma, myositis ossificans, synovial chondromatosis
Indication: Atypical site, atypical imaging, diagnostic doubt
Look for: Homogeneous low T1 signal, variable T2 signal (often low because of calcium), no marrow oedema, no enhancing soft-tissue mass
Caution: Avoid biopsy until MRI and orthopaedic oncology review
Serum: Calcium, phosphate, magnesium, alkaline phosphatase, 25-OH vitamin D, 1,25-(OH)2 vitamin D, PTH, creatinine, eGFR, urate
Urine: 24-hour urinary phosphate (and calcium)
Calculations: Calcium-phosphate product, tubular reabsorption of phosphate (TRP), TmP/GFR
Aim: Separate primary hyperphosphataemic, primary normophosphataemic, secondary uraemic, hyperparathyroidism, vitamin D toxicity
Indications: Child or young adult, sibling cases, consanguinity, recurrence after excision, hyperphosphataemia with normal calcium and PTH
Genes: GALNT3, FGF23, KLOTHO, SLC34A3 (NaPi-IIc), SLC9A3R1 (NHERF1)
Method: Targeted panel or whole-exome sequencing with genetic counselling
Indication: Imaging atypical, mass enlarging rapidly, suspected malignancy, or first presentation in older patient without metabolic risk factors
Approach: Core needle biopsy by orthopaedic oncology service, placed in the planned resection tract
Histology: Lobulated basophilic calcium deposits with surrounding fibrosis, histiocytes and foreign-body giant cells; no atypia
Imaging Pearl
X-ray pattern recognition is often diagnostic. Lobulated, periarticular, 'cloud-like' calcification without cortical or medullary involvement in a young person = tumoral calcinosis until proven otherwise. CT or MRI is for surgical planning, not for diagnosis in the typical case. Always do the metabolic panel before any biopsy - the result may make the biopsy unnecessary.
Expected Lab Pattern by Type
| Lab | Primary Hyper-P | Primary Normo-P | Secondary (CKD) | Dystrophic / Other |
|---|---|---|---|---|
| Serum calcium | Normal | Normal | Low or normal (can be high with binders) | Normal (unless hyperparathyroidism) |
| Serum phosphate | Elevated (often greater than 2 mmol/L) | Normal | Elevated | Variable |
| PTH | Normal or low | Normal | Elevated (secondary hyperparathyroidism) | Variable |
| 1,25-(OH)2 vitamin D | Low / suppressed | Normal | Low (CKD) | Variable |
| FGF23 | Elevated (or inappropriately normal given high PO4) | Normal | Markedly elevated | Normal |
| Renal function | Normal | Normal | Impaired (eGFR reduced or on dialysis) | Normal |
Management Algorithm
Metabolic (Medical) Management - First Line
Goal: Lower serum phosphate, correct the calcium-phosphate product, and stop further deposition. This is the only durable therapy for familial disease and the only curative strategy for secondary uraemic disease.
Medical Protocol
Strict low-phosphate diet: avoid processed meats, cola drinks, dairy excess, nuts and beans
Typical target: dietary phosphate less than 800-1000 mg/day in adults
Dietician input: essential, ideally renal dietician for CKD patients
First-line (non-calcium): Sevelamer hydrochloride or sevelamer carbonate, lanthanum carbonate
Avoid calcium-based binders in patients with hyperphosphataemia and high Ca-P product because they worsen soft-tissue calcification
Dose: titrated to pre-dialysis or fasting serum phosphate
Mechanism: carbonic anhydrase inhibitor - increases renal phosphate excretion
Dose: 250-500 mg twice daily, monitor bicarbonate and potassium
Evidence: case series in familial tumoral calcinosis show mass reduction and phosphate fall
Caution: can worsen acidosis, hypokalaemia; not for advanced CKD
Mechanism: forms soluble calcium thiosulphate complexes
Route: topical (for ulcerated lesions) or intravenous (calciphylaxis-spectrum disease)
Evidence: anecdotal and small case series; not first-line
Hyperparathyroidism: parathyroidectomy, calcimimetics (cinacalcet)
Vitamin D toxicity: stop vitamin D analogues, calcium
Milk-alkali syndrome: stop intake, hydration
CKD-MBD: KDIGO-aligned bundle of diet, binders, dialysis adequacy, vitamin D analogues, calcimimetics
Acetazolamide Pearl
Acetazolamide is a useful adjunct in primary hyperphosphataemic disease because the kidneys are normal and can be coerced to waste more phosphate. It is not useful in uraemic secondary disease - the failing kidneys cannot respond. For uraemic disease, intensify dialysis, switch to non-calcium binders, and consider parathyroidectomy.
Complications
| Complication | Incidence | Risk Factors | Management |
|---|---|---|---|
| Skin ulceration with chalky discharge | Up to 30 percent in uraemic type, lower in familial | Mass size, skin pressure, poor nutrition | Wound care, infection control, complete excision when feasible |
| Secondary infection (cellulitis, abscess, sinus) | 10-20 percent in ulcerated cases | Skin breakdown, immunocompromise (dialysis) | Antibiotics, surgical drainage, excision |
| Joint stiffness / mechanical block | Variable, common with large masses | Mass size, periarticular location | Physiotherapy, surgical excision |
| Nerve compression (sciatic, ulnar, axillary) | Uncommon but disabling | Mass in deep anatomical site | Urgent surgical decompression |
| Recurrence after excision | 50-100 percent in familial, lower in sporadic | Incomplete excision, uncontrolled metabolism | Metabolic control, complete re-excision, transplant if uraemic |
| Wound dehiscence / flap failure | Up to 15 percent in ulcerated uraemic cases | Poor tissue quality, uraemia, diabetes | VAC therapy, flap reconstruction |
| Calciphylaxis (small-vessel calcific vasculopathy) | Rare, but high mortality | Advanced CKD, warfarin, obesity | Sodium thiosulphate, supportive care |
Do Not Biopsy a Parosteal Osteosarcoma Through the Wrong Tract
Tumoral calcinosis is benign and biopsy is safe, but a presumed tumoral calcinosis that turns out to be a parosteal osteosarcoma must have its biopsy performed by the orthopaedic oncology service that will do the definitive resection. A poorly placed biopsy contaminates compartments and may cost the limb. If in doubt, refer for biopsy, do not perform it yourself.
Outcomes and Prognosis
Outcomes by Subtype
| Subtype | Medical Control | Surgical Cure Rate | Long-Term Outlook |
|---|---|---|---|
| Primary hyperphosphataemic (familial) | Good with binders, diet, acetazolamide; new biologics emerging | Low - high recurrence | Lifelong metabolic control; rare renal involvement |
| Primary normophosphataemic (sporadic) | Limited - no metabolic driver to correct | High if completely excised | Excellent if no recurrence; monitor for new lesions |
| Secondary (uraemic / dialysis) | Possible with aggressive CKD-MBD management | Moderate - recurrence if metabolic state uncontrolled | Driven by renal disease; transplant is curative |
| Dystrophic / other | Treat underlying cause | Moderate to high | Cure if underlying cause controlled |
Prognostic Pearls
Best prognosis: Sporadic normophosphataemic disease with complete primary excision; dystrophic disease with treated underlying cause.
Worst prognosis: Familial hyperphosphataemic disease with multiple recurrences; uraemic disease on long-term dialysis with poor metabolic control.
Curative treatment is achievable in two settings only: complete excision of a solitary normophosphataemic mass, and successful renal transplantation in uraemic disease.
The single biggest prognostic factor is whether the metabolic driver can be corrected - and in familial disease it usually cannot be cured, only controlled.
Evidence Base and Key Trials
Proposal for a pathogenesis-based classification of tumoral calcinosis
- Classifies tumoral calcinosis into primary (normophosphataemic and hyperphosphataemic familial) and secondary (uraemic, hyperparathyroidism, vitamin D toxicity, milk-alkali, connective tissue disease) subtypes based on pathogenesis rather than site
- Hyperphosphataemic familial subtype clusters in children of consanguineous parents, with autosomal recessive inheritance and high post-excision recurrence
- Secondary subtype is far more common clinically because of the dialysis population, with calcium-phosphate product as the principal driver
- Treatment is metabolic first in secondary disease, surgical only for symptomatic masses
Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis
- Identified biallelic loss-of-function mutations in GALNT3 as the cause of autosomal recessive hyperphosphataemic familial tumoral calcinosis
- GALNT3 encodes a glycosyltransferase required for O-linked glycosylation and secretion of intact, biologically active FGF23
- Affected patients had elevated serum phosphate, normal calcium, suppressed 1,25-(OH)2 vitamin D, normal or low PTH, and active FGF23 substrate accumulation
- Established the FGF23-GALNT3-KLOTHO axis as central to phosphate handling
A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis
- Identified biallelic FGF23 mutations in a family with autosomal recessive hyperphosphataemic tumoral calcinosis, complementing GALNT3 findings
- FGF23 mutations impair either FGF23 protein stability or receptor binding, leading to loss of phosphaturic signalling
- Patients had the classic biochemical triad - high phosphate, normal calcium, suppressed 1,25-(OH)2 vitamin D
- Demonstrated locus heterogeneity in familial tumoral calcinosis
Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome
- Multicentre NIH-led cohort of 8 patients with familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome, all with hyperphosphataemia, increased tubular reabsorption of phosphate, and elevated or inappropriately normal 1,25-(OH)2 vitamin D
- Biallelic GALNT3 mutations identified in 7 of 8 subjects; FGF23 and KLOTHO recognised as the other causal genes in the FTC/HHS spectrum
- Clinical phenotype ranged from asymptomatic to massive, disabling calcifications, with diaphyseal hyperostosis on radiographs; one subject had complete resolution of a calcific mass after 13 months of medical therapy
- Two subjects with severe calcifications also had overwhelming systemic inflammation that responded to IL-1 antagonists, a novel finding in FTC/HHS
Review of tumoral calcinosis: a rare clinico-pathological entity
- Clinicopathological review of tumoral calcinosis confirming the primary (hyperphosphataemic familial and normophosphataemic sporadic) and secondary (chronic renal failure, hyperparathyroidism) subtypes
- Hyperphosphataemic familial form attributed to mutations in GALNT3, KLOTHO or FGF23; normophosphataemic primary form increasingly linked to SAMD9 variants
- Endorses a stage-oriented approach: phosphate binders, low-phosphate diet and acetazolamide should be tried before surgery in primary disease because of high recurrence and complication rates
- Medical therapy is the mainstay for the secondary uraemic variety, with parathyroidectomy reserved for failure; surgical excision in uraemic patients is a last resort
Exam Viva Scenarios
Use these scenarios to practise clinical reasoning and management decisions
Scenario 1: Hip Mass in a Dialysis Patient
"A 58-year-old man on haemodialysis for 9 years (end-stage renal disease from diabetes) presents with a slowly enlarging, firm, lobulated mass over the greater trochanter of his right hip. It is non-tender, stony-hard, and the overlying skin is intact. He is on calcium carbonate as a phosphate binder and alfacalcidol. Serum calcium is 2.4 mmol/L, phosphate is 2.6 mmol/L, PTH is 850 pg/mL, and 25-OH vitamin D is 30 nmol/L. What is the diagnosis and how do you manage him?"
Scenario 2: Recurrent Mass in a Young Patient with Hyperphosphataemia
"A 14-year-old boy, born to consanguineous parents, presents with recurrent lobulated masses around both hips and his right elbow. He had his first mass excised at age 8 with recurrence within a year. Serum calcium is normal, phosphate is 2.7 mmol/L, PTH is low-normal, 1,25-(OH)2 vitamin D is low, FGF23 is inappropriately normal for the degree of hyperphosphataemia, and renal function is normal. Genetic testing reveals homozygous GALNT3 mutations. How do you counsel and manage him?"
MCQ Practice Points
Pathogenesis Question
Q: What is the molecular basis of autosomal recessive hyperphosphataemic familial tumoral calcinosis? A: Loss-of-function of GALNT3, FGF23 or KLOTHO, leading to impaired FGF23 signalling. GALNT3 glycosylates FGF23 so it can be secreted as an intact, biologically active phosphaturic hormone. Without intact FGF23 signalling, the kidney fails to waste phosphate, leading to hyperphosphataemia, suppressed 1,25-(OH)2 vitamin D, and progressive periarticular hydroxyapatite deposition.
Classification Question
Q: Classify tumoral calcinosis by pathogenesis. A: Using the Smack (1996) classification: primary (idiopathic) - further split into hyperphosphataemic familial (FGF23 axis) and normophosphataemic sporadic; secondary - chronic renal failure / dialysis, hyperparathyroidism, vitamin D toxicity, milk-alkali syndrome; dystrophic - local tissue injury; iatrogenic / miscellaneous - calcium-based binder excess, calcinosis cutis in connective tissue disease. The dominant clinical form is secondary (uraemic).
Imaging Question
Q: What does the plain radiograph show in tumoral calcinosis, and how does it differ from parosteal osteosarcoma? A: Tumoral calcinosis shows a lobulated, periarticular, 'cloud-like' or 'chicken-wire' calcific mass that is not attached to the underlying bone. Parosteal osteosarcoma is a cortically based, mature-bone-forming mass with a 'string sign' on CT, often posterior distal femur, with potential marrow involvement. Biopsy of a suspected parosteal osteosarcoma must be performed by the sarcoma service.
Lab Question
Q: A young patient with periarticular calcific masses has normal calcium, phosphate of 2.6 mmol/L, suppressed 1,25-(OH)2 vitamin D and low-normal PTH. What is the most likely subtype? A: Primary hyperphosphataemic familial tumoral calcinosis. The biochemical pattern is high phosphate with normal calcium, low active vitamin D and low PTH. Most cases are due to biallelic GALNT3, FGF23 or KLOTHO mutations. Genetic testing is indicated.
Treatment Question
Q: What is the first-line treatment for a patient with secondary (uraemic) tumoral calcinosis on dialysis? A: Metabolic correction, not surgery. Switch from calcium-based to non-calcium phosphate binders (sevelamer, lanthanum), intensify dialysis, review vitamin D analogue dose, target pre-dialysis phosphate less than 1.5 mmol/L, and consider parathyroidectomy if PTH remains very high. Surgical excision is reserved for symptomatic (ulcerating, infected, mechanically limiting) masses. Renal transplantation is the only curative metabolic therapy.
Differential Question
Q: How do you distinguish tumoral calcinosis from myositis ossificans? A: Tumoral calcinosis is a periarticular, lobulated, calcium hydroxyapatite mass, typically around the hip, shoulder or elbow, in a patient with a metabolic driver (familial FGF23 axis defect or chronic renal failure). Myositis ossificans is a mature lamellar bone mass within a muscle belly (commonly quadriceps or brachialis), typically after trauma, attached to periosteum, with a peripheral ossified rim and a lucent centre on serial imaging. Tumoral calcinosis does not form bone; myositis ossificans does.
Prognosis Question
Q: What is the recurrence rate after surgical excision of familial hyperphosphataemic tumoral calcinosis? A: High, often greater than 50 percent, sometimes approaching 100 percent after simple debulking. Recurrence is the rule because surgery does not correct the underlying FGF23 axis defect. The only curative approach is metabolic control (phosphate binders, acetazolamide, low-phosphate diet, emerging anti-FGF23 antibodies) and, for solitary normophosphataemic masses, complete primary excision.
Guidelines, Registries & Global Practice
Global Epidemiology
- Tumoral calcinosis is rare worldwide - incidence estimated at roughly 1 in 100,000 to 1 in 1,000,000
- Familial hyperphosphataemic form clusters in populations with high consanguinity - Middle East, North Africa, Turkey, parts of South Asia
- Secondary (uraemic) form is rising globally as the dialysis population grows - the most common clinical scenario in high-income settings
- Endemic clusters of tumoral calcinosis-like lesions have been described in sub-Saharan Africa and Papua New Guinea, often associated with low calcium, high phosphate dietary patterns
- Site distribution is consistent across regions: hip, shoulder, elbow, wrist, hand
Practice Variation by Resource Setting
- High-resource: tertiary orthopaedic oncology and metabolic bone units offer genetic testing, FGF23 assays, modern phosphate binders, calcimimetics, and access to renal transplantation
- Limited-resource: dietary phosphate restriction, low-cost aluminium-based or calcium-magnesium binders, and acetazolamide remain the backbone of therapy; genetic testing rarely available
- Dialysis adequacy is the strongest single modifiable factor in the uraemic form - more frequent or longer sessions are protective
- Surgical excision is widely available but recurrence remains high without metabolic correction
- No global arthroplasty or implant registry is relevant - tumoral calcinosis is a soft-tissue metabolic disease
Society and Reference Guidance (Side by Side)
| Source | Diagnostic Emphasis | Medical Therapy | Surgical Role |
|---|---|---|---|
| KDIGO - CKD-MBD (global) | Treat hyperphosphataemia and raised PTH first; binders, dialysis dose, calcimimetics, parathyroidectomy | Non-calcium binders first in high Ca-P product; cinacalcet for refractory secondary hyperparathyroidism | Excision for symptomatic, ulcerating or infected masses; transplant is curative |
| AAOS / Orthopaedic oncology (US) | Imaging pattern recognition (lobulated periarticular calcification) and biopsy only by sarcoma service when atypical | Treat underlying cause; refer to endocrinology for familial forms | Complete primary excision preferred over debulking; recurrence is high in familial disease |
| BOA / BSSH (UK) | Metabolic workup before any biopsy; X-ray pattern usually diagnostic | Phosphate binders, diet, acetazolamide; genetic testing for familial forms | Excision reserved for symptomatic or diagnostic doubt cases |
| Orphanet / Rare disease networks (Europe) | Recognise as rare disease; centralised reference centres for genetic and metabolic workup | Multidisciplinary metabolic bone service; emerging anti-FGF23 therapy | Surgery adjunctive; conservative and metabolic management first |
Registry and Evidence Note
There is no dedicated registry for tumoral calcinosis, because it is a rare, non-implant, non-arthroplasty disease. The evidence base is dominated by small case series, mechanistic molecular studies, and narrative reviews. Familial disease is best registered through rare-disease networks (Orphanet, NIH GARD) and genotype-specific cohorts. The uraemic form is captured indirectly within CKD-MBD and dialysis registries.
Documentation Essentials (Globally Applicable)
Record in every patient with a periarticular calcific mass:
- Serum calcium, phosphate, PTH, 25-OH vitamin D, 1,25-(OH)2 vitamin D, creatinine, eGFR, urate, alkaline phosphatase
- Urinary phosphate and tubular reabsorption of phosphate
- Family history and consanguinity
- Renal history, dialysis vintage, current binders and vitamin D analogues
- Imaging: X-ray in two views, CT or MRI when atypical
- Biopsy tract (if performed) and the sarcoma service involvement when in doubt
- Plan for metabolic correction and, if needed, referral for genetic testing
A presumed 'tumour' that turns out to be tumoral calcinosis, or vice versa, is a recurring source of complaints worldwide. Always do the metabolic workup before any biopsy unless the imaging is unequivocally diagnostic and the biopsy is being done by the sarcoma service.
Controversies & Areas of Uncertainty
When to offer surgery in familial disease
Familial hyperphosphataemic tumoral calcinosis almost always recurs after surgery, but a young patient with a large, ulcerating, infected mass cannot be left untreated. The threshold for surgery is therefore a clinical decision weighing symptoms, anatomy, recurrence risk, and the patient's wishes. There is no randomised evidence to guide this.
Role of burosumab and anti-FGF23 therapy
Burosumab is licensed for X-linked hypophosphataemia and tumour-induced osteomalacia, where it lowers phosphate by neutralising excess FGF23. In familial hyperphosphataemic tumoral calcinosis, FGF23 is elevated but dysfunctional - the response to burosumab is biologically plausible but unproven. Case reports suggest benefit, but there are no randomised trials, and cost and access are major barriers.
Optimal phosphate target in secondary uraemic disease
KDIGO suggests normalising phosphate in CKD-MBD, but in dialysis patients with established tumoral calcinosis the target is debated. Aggressive phosphate lowering may reduce new lesions but risks overshooting into hypophosphataemia, hungry bone, and adynamic bone disease. Individualised targets are accepted in practice but poorly evidence-based.
Surgical technique: debulk vs complete excision
Complete primary excision is associated with lower recurrence than debulking, but in deep anatomical sites (sciatic notch, subdeltoid) complete excision carries real risk of nerve injury. There is no comparative trial. The pragmatic approach is: complete excision where safe, debulking where complete is unsafe, and aggressive metabolic control regardless.
Value of genetic testing in adults
Genetic testing is clearly useful in children, sibling cases, and consanguineous families. Its value in isolated adult cases, especially in uraemic patients, is less clear. Finding a heterozygous GALNT3 or FGF23 variant may not change management but does affect family counselling.
Cure definition
'Cure' means different things: anatomical (mass gone), biochemical (phosphate normal), genetic (mutation absent - impossible in familial), and patient-centred (symptom-free, functional). Most familial patients achieve only biochemical and patient-centred control, not anatomical cure.
Tumoral Calcinosis
Clinical summary
Definition and Pathology
- •Periarticular, lobulated deposit of calcium hydroxyapatite - not a true neoplasm
- •Mineral is calcium phosphate (hydroxyapatite), not calcium oxalate or CPPD
- •Lobulated architecture with foreign-body giant cell reaction; no cellular atypia
- •Most common sites: hip, shoulder, elbow, wrist
Classification (Smack 1996)
- •Primary hyperphosphataemic (familial) - GALNT3, FGF23, KLOTHO mutations
- •Primary normophosphataemic (sporadic) - often solitary
- •Secondary (uraemic) - chronic renal failure, dialysis, high Ca-P product
- •Dystrophic - local trauma, hyperparathyroidism, vitamin D toxicity, milk-alkali
Diagnosis
- •X-ray: lobulated, 'cloud-like' or 'chicken-wire' periarticular calcification, not attached to bone
- •CT: confirms no cortical continuity; MRI for atypical cases or surgical planning
- •Lab panel: calcium, phosphate, PTH, 25-OH vitamin D, 1,25-(OH)2 vitamin D, creatinine, FGF23, urinary phosphate
- •Biopsy only by sarcoma service when imaging atypical; metabolic workup before biopsy
FGF23 Axis
- •FGF23 is secreted by osteocytes; requires GALNT3 O-glycosylation for intact secretion
- •Binds FGFR1-KLOTHO complex in the kidney to promote phosphate wasting and suppress 1-alpha hydroxylase
- •Loss-of-function of GALNT3, FGF23 or KLOTHO = hyperphosphataemia, suppressed 1,25-(OH)2 vitamin D
- •Net effect: high phosphate, normal calcium, normal or low PTH, periarticular hydroxyapatite
Differential Diagnosis
- •Myositis ossificans - mature lamellar bone in muscle, attached to periosteum, post-trauma
- •Parosteal osteosarcoma - cortically based, mature bone, 'string sign', biopsy only by sarcoma service
- •Synovial osteochondromatosis - intra-articular loose bodies, not periarticular mass
- •Tophaceous gout - urate tophi, hyperuricaemia, joint aspiration with urate crystals
Medical Management
- •Low-phosphate diet (target less than 800-1000 mg/day in adults)
- •Non-calcium phosphate binders (sevelamer, lanthanum) - avoid calcium binders with high Ca-P product
- •Acetazolamide 250-500 mg twice daily - useful in familial, not in uraemic
- •Treat underlying cause: parathyroidectomy, stop vitamin D analogues, transplant in CKD
Surgical Management
- •Indications: ulceration, infection, nerve compression, mechanical block, diagnostic doubt, cosmesis
- •Technique: complete primary extracapsular excision preferred over debulking
- •Recurrence rate: 50-100 percent in familial disease, lower in sporadic
- •Re-excision only for genuinely symptomatic recurrence after metabolic optimisation
Prognosis and Pitfalls
- •Familial disease is controlled, not cured - lifelong phosphate management required
- •Secondary (uraemic) disease can be cured by successful renal transplantation
- •Sporadic normophosphataemic disease has the best prognosis after complete excision
- •Do not biopsy a suspected parosteal osteosarcoma through the wrong tract - refer to sarcoma service